Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
